Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · IEX Real-Time Price · USD
3.880
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for MREO stock have an average target of 7.50, with a low estimate of 7.00 and a high estimate of 8.00. The average target predicts an increase of 93.30% from the current stock price of 3.88.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 20, 2024.
Analyst Ratings
The average analyst rating for MREO stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +106.19% | Jun 20, 2024 |
| Baird | Baird | Buy Initiates $8 | Buy | Initiates | $8 | +106.19% | Jun 13, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +80.41% | Jun 12, 2024 |
| Needham | Needham | Strong Buy Maintains $6 → $7 | Strong Buy | Maintains | $6 → $7 | +80.41% | Jun 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +80.41% | May 16, 2024 |
Financial Forecast
Revenue This Year
16.08M
from 10.00M
Increased by 60.82%
Revenue Next Year
16.79M
from 16.08M
Increased by 4.40%
EPS This Year
0.01
from -0.20
EPS Next Year
-0.01
from 0.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 82.8M | 49.7M | 148.5M | 57.7M | 134.4M |
| Avg | 16.1M | 16.8M | 72.6M | 37.9M | 107.2M |
| Low | n/a | n/a | 1.0M | 19.0M | 80.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 727.8% | 208.8% | 784.2% | -20.6% | 254.6% |
| Avg | 60.8% | 4.4% | 332.7% | -47.8% | 182.9% |
| Low | - | - | -93.9% | -73.8% | 112.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.10 | 0.02 | -0.08 | -0.08 | -0.03 |
| Avg | 0.01 | -0.01 | -0.08 | -0.08 | -0.03 |
| Low | -0.04 | -0.04 | -0.08 | -0.08 | -0.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 353.1% | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.